ID: f9810557-7cc1-410f-b6ab-92fc0c8182a1
Hypothesis
Test hypothesis 2
🎯 Composite 30%💱 $0.50▼36.4%proposed
EvidencePending (0%)📖 0 cit🗣 1 debates✓ 0 support✗ 0 oppose
🧪 Overview
No data yet for this section.
🧬 Mechanism
No curated mechanism pathway recorded for this hypothesis.
⚖️ Evidence
No supporting or contradicting evidence recorded yet.
📖 Linked Papers
No linked papers recorded for this hypothesis yet.
🏥 Translation
💉 Clinical Trials
No clinical trials data linked to this hypothesis yet.
No curated ClinVar variants loaded for this hypothesis.
Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.
No DepMap CRISPR Chronos data found for this gene.
Run python3 scripts/backfill_hypothesis_depmap.py to populate.
🏆 Tournament
🏆 Arenas / Elo
No arena matches recorded yet. Browse Arenas →
📊 Market Indicators
7d Trend
↔
Stable
7d Momentum
▲ 0.0%
Volatility
Low
0.0097
Events (7d)
0
Price History
▼36.4%💾 Resource Usage
No resource usage or linked notebooks recorded for this hypothesis yet.
🔮 Predictions
🔎 Predictions vs Observations2 predictions · 0 with recorded observations
| Prediction | Predicted | Observed | Status | Conf |
|---|---|---|---|---|
| IF the biomarker levels are measured and stratified by disease severity, THEN a monotonic increase or decrease in biomarker concentration will be observed across severity groups within the cross-secti | Linear trend in biomarker levels across severity tiers with Spearman correlation coefficient > 0.4 | — no observation — | pending | 0.50 |
| IF participants receive the experimental intervention versus control, THEN the primary outcome measure will show a statistically significant difference in the expected direction within 12 weeks. | Effect size of at least 0.5 standard deviations between intervention and control groups on the primary measurable endpoint | — no observation — | pending | 0.50 |
🔮 Falsifiable Predictions (2)
pendingconf 50%
IF participants receive the experimental intervention versus control, THEN the primary outcome measure will show a statistically significant difference in the expected direction within 12 weeks.
Predicted outcome: Effect size of at least 0.5 standard deviations between intervention and control groups on the primary measurable endpoint
Falsification: No statistically significant difference between groups (p > 0.05) or effect size < 0.3 SD after 12 weeks of intervention
pendingconf 50%
IF the biomarker levels are measured and stratified by disease severity, THEN a monotonic increase or decrease in biomarker concentration will be observed across severity groups within the cross-sectional assessment.
Predicted outcome: Linear trend in biomarker levels across severity tiers with Spearman correlation coefficient > 0.4
Falsification: No significant trend observed (Spearman ρ < 0.2) or non-monotonic pattern inconsistent with hypothesis direction
▸Metadatasource: v1_phase_c_backfill · origin_type: gap_debate
| source | v1_phase_c_backfill |
| origin_type | gap_debate |
| _schema_version | 1 |
📊 Evidence Profile
Evidence Balance
+0%
Certainty
0%
Debates
0
Incoming
0
Outgoing
0
0 supporting
0 contradicting
0 neutral
Public annotations (0)Annotate on Hypothes.is →
No public annotations yet.